SUMMARY It has previously been demonstrated that met-enkephalin, an endogenous opiate, stimulates gastric acid secretion in man, while naloxone inhibits meal-stimulated acid secretion. In seven healthy subjects the opiate receptor antagonist naloxone was infused in a dose of 10 gg/kg/h during stimulation of gastric acid secretion with pentagastrin 100 ng/kg/h and met-enkephalin 01 pug/kg/h. Naloxone had no effect on pentagastrin-induced acid secretion, whereas metenkephalin-induced acid secretion was completely abolished in both studies without affecting serum gastrin levels, suggesting that the acid inhibitory effect of naloxone is specifically directed towards met-enkephalin-induced acid secretion. The results support the assumption that met-enkephalin participates in the physiological stimulation of gastric acid secretion. 
Opiate receptors and enkephalins were originally discovered in brain tissuel. Subsequently, immunohistochemical studies revealed a wide distribution of enkephalin in the gastrointestinal tract and pancreas, 'both in endocrine cells2 and in peripheral nerves.34 In a previous study met-enkephalin was found to enhance submaximal pentagastrin-stimulated acid secretion in man without affecting serum gastrin levels5. Naloxone, an opiate receptor antagonist, inhibits basal and meal stimulated gastric acid secretion, without affecting serum gastrin concentration in man. 6 On the first day the stability of the acid response during prolonged stimulation with pentagastrin 100 ng/ kg/h was ensured in a control study during intravenous infusion of saline.
On the second day pentagastrin in a dose of 100 ng/ kg/h was administered as a continuous intravenous infusion for three hours. During the last 1 hours Naloxone (Endo Laboratories Inc. Garden City, New York) was added in a dose of 10 gg/kg/h.
On the third day pentagastrin in a dose of 100 ng/ kg/h was infused for 3j hours. During the last two hours a synthetic met-enkephalin analogue (synthetic metenkephalin analogue FK 33824, provided by Sandoz, Basel, Switzerland) was added in a dose of 1.0 1sg/kg/h. In the last one hour naloxone in a dose of 10 Fg/kg/h was also infused. All infusions were administered at a rate of 12 ml/h.
Laboratory analysis
The concentration of H+ was determined by titration 63 with an autotitrator (Radiometer, Copenhagen) to pH 7.0. 51Cr-Edta was determined in a well-counter. In each gastric sample the concentration of Na + was determined by flame photometry and osmolarity by freezing point reduction.
Serum gastrin concentration was measured radioimmunochemically. The gastrin antiserum used (2604) binds component I, II (gastrin 34), and III (gastrin 17) with equimolar potency, while the binding of component IV (gastrin 14) is 60% of that of the larger molecular forms ofgastrin.7 Detection limit, precision and specificity of the assay have been described in details elsewhere.8
Statistical analysis was performed by Student's t test for paired observations.
Results
The control study showed a constant secretory rate during pentagastrin infusion, a secretory plateau was obtained corresponding to a mean acid output of 4.8 ± 0.6 mmol/l H /15 min (Fig. 1) . The addition of naloxone did not alter pentagastrin stimulated gastric acid secretion, output being 4x3±+17 mmol/l H +/ 15 min (p < 0 1). Serum gastrin was unchanged throughout the study (Fig. 2 ). (Fig. 3) .
Mean gastric recovery was 87 ±4.3%, this level being unchanged during the study. Duodenogastric reflux did not occur, as no change in the concentration of Na+ or osmolarity was found.
Discussion
In the present study it has been demonstrated that naloxone does not affect submaximal pentagastrin stimulated gastric acid secretion or serum gastrin concentration. In contrast, met-enkephalin-induced acid response was inhibited by naloxone, also without change in serum gastrin concentration. Consequently, naloxone seems to interfere only with opiate-induced acid secretion. This observation, together with previously reported findings that basal and food-stimulated gastric acid secretion in man inhibited by naloxone,6 suggests that met-enkephalin participates in the physiological acid response. This accords with our previous findings that met-enkephalin seems to be a partial agonist of acid secretion.5 As other parietal cell inhibitors, such as H2-receptor antagonists and atropine, also inhibit opiate-induced gastric acid secretion,9 it is possible that the effect of endogenous opiates involves release of histamine and acetylcholine.
Met-enkephalin has been detected in the vagal nervel1 and it has been suggested that it may play a role in the cephalic phase of gastric acid secretion5. However, in contrast with basal and food-stimulated gastric acid secretion, sham feeding-induced acid secretion was not inhibited by naloxone,"1 indicating that metenkephalin is unlikely to participate in the cephalic phase of acid secretion.
In conclusion, this study has shown that the opiate receptor antagonist, naloxone, inrhibits met-enkephalininduced gastric acid secretion but not pentagastrinstimulated secretion, suggesting that the inhibitory effect of naloxone is specifically directed towards metenkephalin-induced secretion. This observation, together with the findings that naloxone is without effect on sham feeding" but inhibits meal-stimulated acid secretion,6 renders it probable that met-enkephalin participates in the gastric phase of acid secretion. 
